Evaluation of the genotypic prediction of HIV-1 coreceptor use versus a phenotypic assay and correlation with the virological response to maraviroc: the ANRS GenoTropism study.
about
SIVagm infection in wild African green monkeys from South Africa: epidemiology, natural history, and evolutionary considerationsBioinformatic analysis of HIV-1 entry and pathogenesis.Parameters Influencing Baseline HIV-1 Genotypic Tropism Testing Related to Clinical Outcome in Patients on MaravirocReliable genotypic tropism tests for the major HIV-1 subtypesSensitive deep-sequencing-based HIV-1 genotyping assay to simultaneously determine susceptibility to protease, reverse transcriptase, integrase, and maturation inhibitors, as well as HIV-1 coreceptor tropism.Determination of viral tropism by genotyping and phenotyping assays in Brazilian HIV-1-infected patients.An expanded model of HIV cell entry phenotype based on multi-parameter single-cell data.A genotypic test for HIV-1 tropism combining Sanger sequencing with ultradeep sequencing predicts virologic response in treatment-experienced patientsUse of four next-generation sequencing platforms to determine HIV-1 coreceptor tropism.HIV-1 tropism and liver fibrosis in HIV-HCV co-infected patientsHIV-1 tropism determination using a phenotypic Env recombinant viral assay highlights overestimation of CXCR4-usage by genotypic prediction algorithms for CRF01_AE and CRF02_AG [corrected].HIV-1 tropism testing in subjects achieving undetectable HIV-1 RNA: diagnostic accuracy, viral evolution and compartmentalization.Concordance between two phenotypic assays and ultradeep pyrosequencing for determining HIV-1 tropism.Genotypic prediction of HIV-1 subtype D tropismCovariance of charged amino acids at positions 322 and 440 of HIV-1 Env contributes to coreceptor specificity of subtype B viruses, and can be used to improve the performance of V3 sequence-based coreceptor usage prediction algorithms.Impact of mutations outside the V3 region on coreceptor tropism phenotypically assessed in patients infected with HIV-1 subtype BAntiretroviral-Experienced HIV-1-Infected Patients Treated with Maraviroc: Factors Associated with Virological Response.HIV-1 Coreceptor Usage Assessment by Ultra-Deep Pyrosequencing and Response to MaravirocCorrelation of the virological response to short-term maraviroc monotherapy with standard and deep-sequencing-based genotypic tropism prediction methods.Durability and Effectiveness of Maraviroc-Containing Regimens in HIV-1-Infected Individuals with Virological Failure in Routine Clinical PracticeEvolution of proviral DNA HIV-1 tropism under selective pressure of maraviroc-based therapy.Genotypic prediction of HIV-1 CRF01-AE tropism.CoRSeqV3-C: a novel HIV-1 subtype C specific V3 sequence based coreceptor usage prediction algorithmPast, present and future molecular diagnosis and characterization of human immunodeficiency virus infections.Sensitive cell-based assay for determination of human immunodeficiency virus type 1 coreceptor tropism.Comparison of genotypic and phenotypic HIV type 1 tropism assay: results from the screening samples of Cenicriviroc Study 202, a randomized phase II trial in treatment-naive subjects.Longitudinal analysis of HIV-1 coreceptor tropism by single and triplicate HIV-1 RNA and DNA sequencing in patients undergoing successful first-line antiretroviral therapy.The MOTIVATE trials: maraviroc therapy in antiretroviral treatment-experienced HIV-1-infected patients.Effect of HIV-1 subtype and tropism on treatment with chemokine coreceptor entry inhibitors; overview of viral entry inhibition.HIV-1 dynamics and coreceptor usage in Maraviroc-treated patients with ongoing replication.Molecular determinants of HIV-2 R5-X4 tropism in the V3 loop: development of a new genotypic tool.Natural evolution of CD4+ cell count in patients with CD4 >350 or >500 cells/mm3 at the time of diagnosis according to HIV-1 coreceptor tropism.Development of maraviroc, a CCR5 antagonist for treatment of HIV, using a novel tropism assay.Prediction of HIV-1 coreceptor usage (tropism) by sequence analysis using a genotypic approach.Algorithm-based prediction of HIV-1 subtype D coreceptor useGenotypic prediction of human immunodeficiency virus type 1 tropism by use of plasma and peripheral blood mononuclear cells in the routine clinical laboratory.Discordance in HIV-1 co-receptor use prediction by different genotypic algorithms and phenotype assay: intermediate profile in relation to concordant predictions.
P2860
Q27340281-405CC5AC-1AB3-418E-8286-F98148C79831Q27693321-B83E1C66-DB2A-48AF-A416-C196FDBAD4C0Q28547216-C3400F75-C34C-4E40-B0FC-525CF51D7E3AQ30372085-B09D6177-E1EC-4E68-902F-3EA48DAAE208Q33622927-DF1EF131-C10D-47F2-A429-87035663A4BBQ34040770-6A9A3197-1F3F-4F0A-AAF5-53105DAB0969Q34351378-C781AB71-7938-4CEF-85DD-ED3DE69D9D62Q34431102-05079740-EC37-49C0-8BC1-ABFD12E13931Q34482589-7BD9F0D5-9A67-4058-A448-2A05EEBB02BBQ34505231-7D33211E-DCBC-462D-8CD3-B8062BAAECF9Q34716813-60EACA06-18CF-40EA-9137-20DC9D864466Q34923915-5F157F2E-85A0-44B2-B2FA-6DFD55FA4A79Q35004817-21D67AD0-1A35-46CA-BD10-3F5CF729EB64Q35137552-8D51F93F-439A-43DE-84B7-E60BF16639EDQ35330357-0241982E-F495-4A62-BF03-A8F1F06B3F2BQ35364051-CD7296A3-89E8-4A8D-AADA-C6BC528824FEQ35589798-5317A694-C128-47FB-AD20-B9CAA76FBBA2Q35662019-2981CDE8-C6D6-41EB-A185-B086005741D4Q35806266-DA6D09B2-A801-4892-BAE5-AB75455FFA1CQ35880629-E7AE3854-301B-4A15-983F-3A2D8737F356Q35953203-42A3C72B-7D1D-4D19-BDE9-ABF410BD1DC9Q36559004-53124F97-486E-433A-950B-7603B2089EE1Q36690585-371D9050-5364-4E83-9CDE-A67C74601A13Q36779718-BBBAF45C-F147-47BA-8563-0BBD07C6224DQ36826759-3ACAE8F5-461D-4C58-B888-B29F509E7CD6Q37547823-04101B95-1F11-4866-A0A6-23EE374B1C54Q37637067-83CFDC03-EFB4-4FC1-9B54-6C94EA9D3AB5Q38056759-7238F5F4-6305-4130-B065-DC0663364C4FQ38196457-308FF480-9972-4DA2-9345-E295899C3CFCQ39388518-0FD6DBD9-9226-41CC-8873-68AB68D17D49Q39433148-615F84EE-378E-4F05-8BE6-90DC204D14BCQ39480583-49290F52-A4B5-414E-9ABA-5BC3B93D101DQ39549270-E3EDD4B2-BC27-4576-A4C1-0BE7D3A6ADD5Q42186680-C711B768-E6BC-4B30-93D4-6CE4371D186EQ42287937-3175274F-488D-4A33-B0CB-0B643AC56817Q42850302-447D2C85-B90E-471E-9E39-D9EC47A0092CQ51450830-907DE380-5D97-4F7E-A10E-35AE69B8828C
P2860
Evaluation of the genotypic prediction of HIV-1 coreceptor use versus a phenotypic assay and correlation with the virological response to maraviroc: the ANRS GenoTropism study.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Evaluation of the genotypic pr ...... c: the ANRS GenoTropism study.
@ast
Evaluation of the genotypic pr ...... c: the ANRS GenoTropism study.
@en
Evaluation of the genotypic pr ...... c: the ANRS GenoTropism study.
@nl
type
label
Evaluation of the genotypic pr ...... c: the ANRS GenoTropism study.
@ast
Evaluation of the genotypic pr ...... c: the ANRS GenoTropism study.
@en
Evaluation of the genotypic pr ...... c: the ANRS GenoTropism study.
@nl
prefLabel
Evaluation of the genotypic pr ...... c: the ANRS GenoTropism study.
@ast
Evaluation of the genotypic pr ...... c: the ANRS GenoTropism study.
@en
Evaluation of the genotypic pr ...... c: the ANRS GenoTropism study.
@nl
P2093
P2860
P50
P356
P1476
Evaluation of the genotypic pr ...... c: the ANRS GenoTropism study.
@en
P2093
Anne-Geneviève Marcelin
Annick Ruffault
Astrid Vabret
Bernard Masquelier
Brigitte Montes
Catherine Tamalet
Cathia Soulié
Coralie Pallier
Delphine Desbois
Jacqueline Cottalorda
P2860
P304
P356
10.1128/AAC.00148-10
P407
P50
P577
2010-06-07T00:00:00Z